The invention relates to biomarkers useful for distinguishing Bipolar Disorder 1 (BPD1), Bipolar Disorder 2 (BPD2), and Major Depressive Disorder (MDD) and to methods for use of said biomarkers in differential diagnosis, treatment, altering treatment and generating quantitative data.